Cardiovascular, kidney-related and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline

Published by Arnav Agarwal on Aug 14, 2025

View

Disclaimer

Sponsors

Contact

Abstract

Language

en-ca

PICOS

PICO 10.1

Population
Adults with type 2 diabetes at lower risk (updated July 2024)
Intervention
SGLT-2 inhibitors
Comparator
Standard care
Outcomes

PICO 10.2

Population
Adults with type 2 diabetes at lower risk (updated July 2024)
Intervention
GLP-1 receptor agonists
Comparator
Standard care
Outcomes

PICO 20.1

Population
Adults with type 2 diabetes at moderate risk (updated July 2024)
Intervention
SGLT-2 inhibitors
Comparator
Standard care
Outcomes

PICO 20.2

Population
Adults with type 2 diabetes at moderate risk (updated July 2024)
Intervention
GLP-1 receptor agonists
Comparator
Standard care
Outcomes

PICO 20.3

Population
Adults with type 2 diabetes at moderate risk (updated July 2024)
Intervention
Finerenone
Comparator
Standard care
Outcomes

PICO 30.1

Population
Individuals with diabetes (low, moderate and high risk)
Intervention
SGLT-2 inhibitors
Comparator
Standard care
Outcomes

PICO 30.1

Population
Adults with type 2 diabetes at higher risk (updated July 2024)
Intervention
SGLT-2 inhibitors
Comparator
Standard care
Outcomes

PICO 30.2

Population
Individuals with diabetes (low, moderate, high risk)
Intervention
GLP-1 receptor agonists
Comparator
Standard care
Outcomes

PICO 30.2

Population
Adults with type 2 diabetes at higher risk (updated July 2024)
Intervention
GLP-1 receptor agonists
Comparator
Standard care
Outcomes

PICO 30.3

Population
Individuals with diabetes and CKD (moderate, high risk)
Intervention
Finerenone
Comparator
Standard care
Outcomes

PICO 30.3

Population
Adults with type 2 diabetes at higher risk (updated July 2024)
Intervention
Finerenone
Comparator
Standard care
Outcomes

PICO 30.4

Population
Individuals with diabetes (low, moderate, high risk)
Intervention
Tirzepatide
Comparator
Standard care
Outcomes

PICO 30.5

Population
Individuals with diabetes (low, moderate, high risk)
Intervention
SGLT-2 inhibitors
Comparator
GLP-1 receptor agonists
Outcomes

PICO 30.6

Population
Individuals with diabetes (low, moderate, high risk)
Intervention
GLP-1 receptor agonists
Comparator
Tirzepatide
Outcomes

PICO 40.1

Population
Adults with type 2 diabetes and obesity (across risk strata) (updated July 2024)
Intervention
Tirzepatide
Comparator
Standard care
Outcomes